RAMAT GAN, Israel--(BUSINESS WIRE)--IOPtima announced today that it has completed development of its OT134 device, a novel laser-based therapy for the treatment of glaucoma. The second-generation OT134 is based on IOPtima’s smart laser-based technology known as LNPDS (CO2 Laser Non-Penetrating Deep Sclerectomy) that has already been successfully tested on 23 glaucoma patients in clinical trials. The OT134 upgrades the previous prototype with improved efficacy and ergonomic features.
